Published in Lab Business Week, September 25th, 2005
The company also filed an investigational new drug application (IND) with the U.S. Food and Drug Administration for approval to begin human clinical trials to evaluate the company's second drug candidate AL-208 as a treatment for mild cognitive impairment (MCI) associated with cardiac artery bypass graft (CABG) surgery. Allon will commence...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.